The Department of Health and Human Services on Sunday said nine major drugmakers have now signed voluntary pricing agreements tied to President Donald Trump’s most-favored-nation push, framing the tally as proof that manufacturers are moving before the Nov. 1 Medicare open-enrollment window and a midterm election season dominated by health costs. For seniors comparing Part D plans, the practical test is whether any line item on a January pharmacy receipt looks cheaper—not how many companies signed a pledge in Washington.

What HHS is claiming

Assistant Secretary for Planning and Evaluation officials told reporters that Pfizer, Merck, Johnson & Johnson, AbbVie, Bristol Myers Squibb, Amgen, Gilead, Regeneron and Sanofi have each filed binding commitments to align U.S. list prices for selected products with the lowest price charged in comparable wealthy countries, expand direct-to-patient discounts through TrumpRx.gov, and route Medicaid savings through state agencies. HHS did not publish product-level price tables on Sunday, but said a consolidated “MFN index” would post when CMS opens its plan finder on Oct. 1.

The announcement builds on Pfizer’s September 2025 pact, the first after Trump threatened 100% tariffs on imported branded medicines. That deal focused on Medicaid rebates and a direct-purchase channel; Medicare Part D was largely untouched in the public terms. HHS now says six of the nine companies extended MFN language to at least one Part D blockbuster, with negotiated rates to appear in 2027 plan bids rather than this fall’s enrollment packets.

Where Medicare enrollees still wait

CMS reminded beneficiaries that 2026 open enrollment runs Nov. 1 through Dec. 7 for coverage starting Jan. 1. The Inflation Reduction Act’s first negotiated prices for 10 Part D drugs take effect Jan. 1, 2026, while a second negotiation cycle covers 15 additional medicines with prices delayed until 2027. HHS’s Sunday slide deck counted those statutory negotiations separately from the voluntary MFN deals, a distinction patient groups said matters when candidates claim “nine companies cut prices” on the stump.

“A pledge on tomorrow’s launch pipeline does not change what a 72-year-old pays for insulin in November,” said Leslie Dach, who chairs Protect Our Care, a coalition that backs the IRA program. HHS countered that direct-purchase discounts of 40% to 85% off list for primary-care brands would be live on TrumpRx.gov before enrollment ads hit cable news.

Politics and the evidence gap

Republican strategists have told state parties to feature drug pricing in suburban House districts where hospital margins are squeezed by labor costs and where Medicare Advantage star-rating fights already clutter mailboxes. Democrats plan to contrast voluntary deals with IRA negotiation, arguing statutory ceilings beat handshake discounts that can vanish with a tariff tweet.

Actuaries at Milliman said employers covering workers under 65 should assume little spillover from Medicaid-focused rebates. Medicaid accounts for roughly a tenth of U.S. drug spending; employer plans and cash payers remain the largest buckets untouched by Sunday’s count. HHS promised a public comment period on how MFN prices would interact with Part D reinsurance, but offered no timeline.

For now, nine signatures give the administration a midterm talking point. Whether they move the median senior’s premium depends on plan bids insurers file in October—numbers HHS has not yet released.